Lexicon Pharmaceuticals (LXRX) Liabilities and Shareholders Equity (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $268.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 9.69% year-over-year to $268.8 million; the TTM figure through Mar 2026 stood at $885.3 million (down 31.4% YoY), while the FY2025 annual figure was $185.0 million, down 38.01% from the prior year.
• Liabilities and Shareholders Equity advanced to $268.8 million in Q1 2026 per LXRX's latest filing, from $185.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $417.2 million in Q1 2024 and bottomed at $112.3 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $247.8 million across 5 years, with a median of $229.4 million in 2023.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity soared 181.97% — and 2025, when it sank 39.58%.
• Lexicon Pharmaceuticals' Liabilities and Shareholders Equity stood at $194.3 million in 2022, then gained by 18.08% to $229.4 million in 2023, then jumped by 30.07% to $298.4 million in 2024, then slumped by 38.01% to $185.0 million in 2025, then soared by 45.32% to $268.8 million in 2026.
• Business Quant data shows LXRX's Liabilities and Shareholders Equity at $268.8 million in Q1 2026, $185.0 million in Q4 2025, and $205.9 million in Q3 2025.